Bermuda Run

This research aims to find better ways to support older adults and their family caregivers during the transition from hospital to home. It compares two acute care transition programs to see if adding family caregiver support to patient-focused care helps patients stay safely at home and reduces the time they spend in hospitals or emergency rooms. The study also looks at whether this family-centered approach improves patients ability to carry out daily activities and reduces caregiving burden. Participants will be randomly assigned to one of two groups. The first group receives an active care transition program focused on patient needs, including assessments, discharge planning, education, and follow-up. The second group receives the same patient-focused program plus additional family caregiver support such as caregiver needs assessment, structured education, and skill building. The study uses telephone, video calls, and other technologies to involve families across urban and rural areas in five states. During the study, participants and their family caregivers will be assessed through surveys and interviews at multiple time points up to 180 days after discharge. Researchers will measure hospital-free days, readmissions, patient and caregiver outcomes like caregiver burden, social role participation, and satisfaction with care transitions. The study also tracks access to community services, outpatient follow-up, and cognitive status, aiming to better understand and improve the hospital-to-home transition experience for older adults and their families.

Researchers are evaluating the safety of Ex Vivo Cross Linking CXL of donor corneal tissue in people who have undergone high-risk penetrating keratoplasty, a type of corneal transplant. This randomized, double-masked, multi-site clinical trial involves 96 participants and focuses on those with vascularized high-risk corneal conditions. The study aims to better understand the safety of this treatment approach over a 24-month period. Participants will be randomly assigned to one of two groups one group will receive donor corneal tissue treated with 0.1% riboflavin Vitamin B2 and 20% dextran Photrexa Viscous & Photrexa combined with UV light, while the other group will receive untreated donor corneal tissue. The treated tissue is prepared by a Corneal Tissue Bank following strict Current-Good-Tissue-Practice CGTP guidelines. Both groups will be monitored for two years after transplantation to track any adverse events. During the study, participants will have regular assessments to monitor safety, graft failure, and graft rejection rates. Researchers will also evaluate the efficacy of the corneal cross linking through image reviews. The trial includes a follow-up period of 24 months post-transplantation to carefully observe outcomes and ensure comprehensive safety monitoring throughout the study duration.

Researchers are compiling real-world outcomes of the commercially approved Intracept2 Intraosseous Nerve Ablation Systems for treating patients diagnosed with vertebrogenic pain, including those with chronic low-back pain and vertebrogenic pain syndrome. This observational study aims to gather data on how this minimally invasive device performs in routine clinical use. Participants who are scheduled for treatment with the Intracept2 Intraosseous Nerve Ablation System will be observed following their procedure according to local instructions. The study focuses on patients receiving this commercially approved device without altering their treatment plan. Throughout the study, participants will have their disability levels assessed using the Oswestry Disability Index ODI from baseline up to 60 months after the procedure. Data collected will help understand the long-term effects of the device on pain and disability. The total duration of participation may extend up to five years post-treatment.